©2024 Stanford Medicine
Subcutaneous Botulinum Toxin for Cutaneous Allodynia
Not Recruiting
Trial ID: NCT00725322
Purpose
Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has
also been reported to be helpful for some pain conditions. The investigators have observed
prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin
Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to
study if addition of BTA extends pain relief compared to placebo when injected subcutaneously
into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is
perceived as painful).
Official Title
Subcutaneous Botulinum Toxin for Cutaneous Allodynia
Eligibility
Inclusion Criteria:- Moderate to severe pain (greater than 4/10) of duration more than 6
months despite previous therapy.
- The patient exhibits at least 80% pain relief following injection of local anesthetic
subcutaneously into scar as assessed by change in NRS
- The patient reports the presence of hyperalgesia, allodynia, dysesthesia, or
hypoesthesia surrounding the scar
- Age 18-100
- Ability to read, write, and converse in English, provide informed consent, and follow
study procedures
Exclusion Criteria:
1. Any neuromuscular disorder such as myasthenia gravis, eaton lambert, muscular
dystrophy
2. Any ongoing legal action related to their pain
3. Allergy to local anesthetics
4. A current or history of any severe psychiatric disorder
5. History of any adverse reaction to botulinum toxin
6. History of botulism
7. Untreated infection
8. Coagulopathy
9. Females - positive pregnancy test
10. Surgery within the past 6 months at the site of the painful scar
Intervention(s):
drug: Botulinum Toxin A
drug: Placebo - Saline
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rachel Moericke
6507240522